v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table summarizes the segment's financial information including the Company’s significant segment expenses:
Three Months Ended
June 30,		Six Months Ended June 30,
2026202520262025
Revenue:
Research and development services and royalty revenue
$187,546 $(21,172)$340,001 $4,255 
Total revenue187,546 (21,172)340,001 4,255 
Cost of revenues319,889 — 562,214 — 
Segment operating expenses:
Research and development:
Direct program costs:
Ovaprene (1)
843,503 1,316,372 2,075,263 2,812,101 
Sildenafil Cream (2)
134,769 49,881 202,560 261,270 
Other advanced clinical stage programs1,244,028 975,489 1,619,791 1,466,051 
Phase 1 and Phase 1-ready clinical stage programs (1)
164,068 628,595 260,123 1,125,342 
Preclinical stage programs1,457,723 1,718,320 2,626,102 2,767,058 
Personnel-related (including stock-based compensation)1,084,019 1,209,437 2,276,881 2,701,684 
Contra-R&D expenses (3)
(4,017,949)(3,780,794)(7,087,095)(6,399,167)
Total research and development direct program costs910,161 2,117,300 1,973,625 4,734,339 
Indirect costs:
Other indirect costs30,654 70,462 59,500 199,196 
Contra R&D expenses(698,849)(759,000)(1,130,697)(1,207,392)
Total research and development indirect costs(668,195)(688,538)(1,071,197)(1,008,196)
Total research and development241,966 1,428,762 902,428 3,726,143 
Selling, general and administrative2,593,671 2,377,866 4,842,237 4,687,030 
Total segment operating expenses2,835,637 3,806,628 5,744,665 8,413,173 
Loss from operations(2,967,980)(3,827,800)(5,966,878)(8,408,918)
Interest expense190,965 268,532 390,359 402,583 
Interest income(176,145)(69,847)(367,833)(226,469)
Other income, net
27 10,002 6,742 190,242 
Net loss$(2,982,773)$(4,016,483)$(5,982,662)$(8,394,790)
(1)The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (3) below.
(2)The amount of expenses includes expenses for Sildenafil Cream, 3.6% and DARE to PLAY Sildenafil Cream.
(3)These contra R&D expenses were recognized as follows for the three months ended June 30, 2026 and 2025: (a) Ovaprene, $0.8 million and $0.4 million, respectively; (b) other advanced clinical stage programs, $1.3 million and $1.0 million, respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0 and $0.1 million, respectively; and (d) preclinical stage programs, $1.9 million and $2.2 million, respectively.
These contra R&D expenses were recognized as follows for the six months ended June 30, 2026 and 2025: (a) Ovaprene, $1.7 million and $0.9 million, respectively; (b) other advanced clinical stage programs, $1.8 million and $1.5 million, respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0 million and $0.2 million, respectively; and (d) preclinical stage programs, $3.6 million and $3.8 million, respectively.